NASDAQ:TNYA Tenaya Therapeutics (TNYA) Stock Price, News & Analysis $2.15 +0.40 (+22.86%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Tenaya Therapeutics Stock (NASDAQ:TNYA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Tenaya Therapeutics alerts:Sign Up Key Stats Today's Range$1.73▼$2.1650-Day Range$1.64▼$3.0552-Week Range$1.61▼$7.01Volume1.09 million shsAverage Volume456,512 shsMarket Capitalization$169.61 millionP/E RatioN/ADividend YieldN/APrice Target$15.25Consensus RatingBuy Company OverviewTenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Read More… Crypto’s next big bull run? (Ad)Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on November 5. Just a day after the American election, Juan believes crypto could start a massive run up …And one special coin could do even better. Tenaya Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks57th Percentile Overall ScoreTNYA MarketRank™: Tenaya Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 533rd out of 1,012 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingTenaya Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTenaya Therapeutics has received no research coverage in the past 90 days.Read more about Tenaya Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Earnings GrowthEarnings for Tenaya Therapeutics are expected to remain at ($1.52) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tenaya Therapeutics is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tenaya Therapeutics is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTenaya Therapeutics has a P/B Ratio of 1.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Tenaya Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.78% of the float of Tenaya Therapeutics has been sold short.Short Interest Ratio / Days to CoverTenaya Therapeutics has a short interest ratio ("days to cover") of 12.9, which indicates bearish sentiment.Change versus previous monthShort interest in Tenaya Therapeutics has recently decreased by 2.68%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTenaya Therapeutics does not currently pay a dividend.Dividend GrowthTenaya Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.78% of the float of Tenaya Therapeutics has been sold short.Short Interest Ratio / Days to CoverTenaya Therapeutics has a short interest ratio ("days to cover") of 12.9, which indicates bearish sentiment.Change versus previous monthShort interest in Tenaya Therapeutics has recently decreased by 2.68%, indicating that investor sentiment is improving. News and Social Media3.3 / 5News Sentiment0.93 News SentimentTenaya Therapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Tenaya Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for TNYA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added Tenaya Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Tenaya Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $56,468.00 in company stock.Percentage Held by Insiders32.76% of the stock of Tenaya Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions90.54% of the stock of Tenaya Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tenaya Therapeutics' insider trading history. Receive TNYA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tenaya Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TNYA Stock News HeadlinesTenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCMOctober 17 at 4:30 PM | globenewswire.comReviewing Tenaya Therapeutics (NASDAQ:TNYA) & IN8bio (NASDAQ:INAB)October 14, 2024 | americanbankingnews.comWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.October 18, 2024 | Porter & Company (Ad)Tenaya Therapeutics (NASDAQ:TNYA) Stock, Short Interest ReportOctober 5, 2024 | benzinga.comTenaya Therapeutics (NASDAQ:TNYA) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comOptimistic Buy Rating for Tenaya Therapeutics as Clinical Milestone Nears in Gene Therapy for CardiomyopathyOctober 2, 2024 | markets.businessinsider.comBuy Rating Reiterated on Tenaya Therapeutics Amid Promising Gene Therapy Prospects for HCMSeptember 24, 2024 | markets.businessinsider.comOwning 43% shares,institutional owners seem interested in Tenaya Therapeutics, Inc. (NASDAQ:TNYA),September 21, 2024 | finance.yahoo.comSee More Headlines TNYA Stock Analysis - Frequently Asked Questions How have TNYA shares performed this year? Tenaya Therapeutics' stock was trading at $3.24 at the start of the year. Since then, TNYA stock has decreased by 33.6% and is now trading at $2.15. View the best growth stocks for 2024 here. How were Tenaya Therapeutics' earnings last quarter? Tenaya Therapeutics, Inc. (NASDAQ:TNYA) released its quarterly earnings data on Thursday, August, 8th. The company reported ($0.34) earnings per share for the quarter, topping analysts' consensus estimates of ($0.40) by $0.06. When did Tenaya Therapeutics IPO? Tenaya Therapeutics (TNYA) raised $150 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Who are Tenaya Therapeutics' major shareholders? Tenaya Therapeutics' top institutional shareholders include SG Americas Securities LLC (0.03%). Insiders that own company stock include Group Gp Lp Column III, David V Goeddel, Deepak Srivastava, Timothy Hoey, Faraz Ali, Whittemore Tingley and Chihiro Saito. View institutional ownership trends. How do I buy shares of Tenaya Therapeutics? Shares of TNYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Tenaya Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tenaya Therapeutics investors own include Voyager Therapeutics (VYGR), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings8/08/2024Today10/17/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TNYA CUSIPN/A CIK1858848 Webwww.tenayatherapeutics.com Phone650-825-6990FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Stock Price Target$15.25 High Stock Price Target$20.00 Low Stock Price Target$7.00 Potential Upside/Downside+609.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-124,080,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-80.97% Return on Assets-67.83% Debt Debt-to-Equity RatioN/A Current Ratio6.28 Quick Ratio6.28 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.05 per share Price / Book1.05Miscellaneous Outstanding Shares78,890,000Free Float53,045,000Market Cap$169.61 million OptionableOptionable Beta2.35 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:TNYA) was last updated on 10/18/2024 by MarketBeat.com Staff From Our PartnersDon’t Buy Another Stock Until Reading This…Buying stocks in today's market is a gamble… Unless you're using the right proven strategy! During my up...Unstoppable Prosperity | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored320 hedge funds just sold this stock320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are alr...Chaikin Analytics | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adopti...Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredEquation for Profits: Volatility = OpportunityFREE Intro to Options Class Online Tonight Prosper Trading Academy | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenaya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenaya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.